NCT06505824

A Study of BL-M14D1 in Patients With Locally Advanced or Metastatic Small Cell Lung Cancer, Neuroendocrine Tumors and Other Solid Tumors

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics Characteristics and Preliminary Efficacy of BL-M14D1 in Patients With Locally Advanced or Metastatic Small Cell Lung Cancer, Neuroendocrine Tumors and Other Solid Tumors

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 22 (estimated)
• Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This study is an open, multicenter, dose-escalation and expansion-enrollment nonrandomized phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of BL-M14D1 in locally advanced or metastatic solid tumors.

Conditions

• Small Cell Lung Cancer
• Neuroendocrine Tumors

Interventions

Type	Name	Description
DRUG	BL-M14D1	Administration by intravenous infusion for a cycle of 3 weeks.

Timeline

• Start date: 2024-08-02
• Primary completion: 2026-08-01
• Completion: 2026-08-01
• First posted: 2024-07-17
• Last updated: 2025-09-18

Locations

1 site across 1 country: China